Impact of ABO-Incompatible Donor on Early and Late Outcome of Hematopoietic Stem Cell Transplantation

Yeğin, Zeynep Arzu; Yenicesu, İdil; Aki, Şahika Zeynep; Yağcı, Münci; Sucak, Gülsan Türköz

doi:10.1016/j.transproceed.2009.06.189

Cited by 40 publications

(57 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others have found a correlation with minor ABOincompatible transplants only for severe (grades III and IV) aGvHD 2,28 or, in one study, only with clinically insignificant (grade I) aGvHD. 20 A decreased risk of aGvHD for recipients of major ABO-incompatible grafts was not observed in the other cohort studies (Table 3b).…”

Section: Does Abo Incompatibility Affect Neutrophil and Platelet Engrmentioning

confidence: 87%

“…[24][25][26][27][28][29][30][31][32][33] Four large registry studies of HPC recipients including two studies of unrelated donor transplantation showed inconsistent results with some deleterious effect on engraftment, GvHD or survival being observed in some patient groups but not in others (Table 3a). Registry data studies strictly limited to PBPC Shown are the chromosome locations of the major HLA and various RBC antigens for which post transplant hemolytic reactions have been reported.…”

Section: Clinical Outcomes Of Rbc-incompatible Transplantsmentioning

confidence: 99%

“…1,2,7,10,11,13,18,21,22,25,27,28 No clear effects of ABO incompatibility have been found for neutrophil or platelet engraftments even though cells of these lineages express ABO antigens or can adsorb antigen from the plasma of secretors. 49 Two of the four registry studies correlated major ABO incompatibility with a median one or two day slower neutrophil engraftment after BMT, 2,8 but a third equally large study involving unrelated donors did not find a difference.…”

Section: Does Abo Incompatibility Affect Neutrophil and Platelet Engrmentioning

confidence: 99%

See 2 more Smart Citations

Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation

Rowley

Donato

Bhattacharyya

2011

Bone Marrow Transplant

121

104

View full text Add to dashboard Cite

Section: Does Abo Incompatibility Affect Neutrophil and Platelet Engrmentioning

confidence: 87%

Section: Clinical Outcomes Of Rbc-incompatible Transplantsmentioning

confidence: 99%

Section: Does Abo Incompatibility Affect Neutrophil and Platelet Engrmentioning

confidence: 99%

See 1 more Smart Citation

Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation

Rowley

Donato

Bhattacharyya

2011

Bone Marrow Transplant

121

104

View full text Add to dashboard Cite

“…Increased incidence of both acute and chronic GVHD have previously been reported in the context of ABO mismatch, although the mechanism is uncertain. 2,12,24 One proposed mechanism is that the persistence of ABO antigens on endothelial-derived von Willebrand factor leads to binding of isoagglutinins to host endothelium, triggering GVHD. 16,46 In addition, ABO glycosyltransferase phenotypes at protein level can generate T-cell responses and act as allogeneic MN histocompatibility antigens.…”

Section: Gvhdmentioning

confidence: 99%

“…21 The impact of ABO mismatch on transplant outcomes is variable, with a number of small and heterogeneous studies in the literature. 4,8,[22][23][24][25][26][27][28][29] Of the larger studies, a French registry study of 1108 RIC HSCT patients reported that MN ABO incompatibility was associated with reduced OS. 30 In the RIC subgroup of the largest registry study to date, Kimura et al 2 reported increased transplantrelated mortality (TRM) for MN, MJ and BD ABO-mismatched patients.…”

Section: Introductionmentioning

confidence: 99%

Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT

Brierley

Littlewood

Peniket

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

The impact of ABO incompatibility on clinical outcomes following haematopoietic SCT (HSCT) remains controversial. This retrospective study assessed the effect of ABO mismatch on transplant outcomes and transfusion requirements in 594 patients undergoing reduced-intensity conditioned (RIC) HSCT with alemtuzumab in three UK transplant centres. We found no significant effects of minor, major or bidirectional ABO mismatch on overall survival, relapse-free survival, nonrelapse mortality or relapse incidence. Although the rate of acute GVHD was unaffected by ABO mismatch, the incidence of extensive chronic GVHD was higher in patients with minor and major mismatch compared with those who were ABO matched (hazard ratio (HR) 1.74, P = 0.032 for minor, HR 1.69 P = 0.0036 for major mismatch). Red cell and platelet transfusion requirements in the first 100 days post transplant did not differ by ABO mismatch. In this large UK series, ABO mismatch in RIC HSCT has no clinically significant effect on survival outcomes but appears to modify susceptibility to extensive chronic GVHD.Bone Marrow Transplantation (2015) 50, 931-938;

show abstract

ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT

et al. 2017

View full text Add to dashboard Cite

ABO incompatibility is commonly observed in stem cell transplantation and its impact in this setting has been extensively investigated. HLA-mismatched unrelated donors (MMURD) are often used as an alternative stem cell source but are associated with increased transplant related complications. Whether ABO incompatibility affects outcome in MMURD transplantation for acute myeloid leukemia (AML) patients is unknown. We evaluated 1,013 AML patients who underwent MMURD transplantation between 2005 and 2014. Engraftment rates were comparable between ABO matched and mismatched patients, as were relapse incidence [34%; 95% confidence interval (CI), 28-39; for ABO matched vs. 36%; 95% CI, 32-40; for ABO mismatched; P 5 .32], and nonrelapse mortality (28%; 95% CI, 23-33; for ABO matched vs. 25%; 95% CI, 21-29; for ABO mismatched; P 5 .2). Three year survival was 40% for ABO matched and 43% for ABO mismatched patients (P 5 .35), Leukemia free survival rates were also comparable between groups (37%; 95% CI, 32-43; for ABO matched vs. 38%; 95% CI, 33-42; for ABO mismatched; P 5 .87).Incidence of grade II-IV acute graft versus host disease was marginally lower in patients with major ABO mismatching (Hazard ratio of 0.7, 95% CI, 0.5-1; P 5 .049]. ABO incompatibility probably has no significant clinical implications in MMURD transplantation.

show abstract

Impact of ABO-Incompatible Donor on Early and Late Outcome of Hematopoietic Stem Cell Transplantation

Cited by 40 publications

References 49 publications

Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation

Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation

Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT

ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT

Contact Info

Product

Resources

About